CEDOC Research


The general objectives of CEDOC are to form an internationally-recognized Center of excellence in Biomedical, Translational and Clinical Research on chronic diseases; to stimulate collaborative research between groups within the CEDOC; to strengthen research quality and innovation and to promote multidisciplinary projects within and beyond the Center; to provide an exciting research environment for the training of Postdoctoral Fellows, PhD and Master funding at national and international levels; and to simulate the organization of outreach activities at local and national levels.

Biomedical Research

CEDOC’s Biomedical research groups are multidisciplinary in nature, using existing knowledge from basic research and methodically expanding it to address a specific medical problem. The Biomedical Research they produce is oriented to understanding the causes of disease of various chronic pathologies, from diabetes and cancer to rare autoimmune diseases.

Research Groups


Biomedical Resources & Services


Clinical Resources & Services


Rare Diseases' Research

Twinning project LYSOCIL aims to strengthen the research and innovation capacity of CEDOC and NMS|FCM, on the field of rare diseases, namely lysosomal diseases and ciliopathies. As such, several dissemination actions are being developed, including exchanges, workshops, retreats, and other activities aimed towards clinicians, patients and family members, patient associations and researchers, together with Munster University (WWU) and Telethon Institute of Genetics and Medicine (TIGEM).
To know more about LYSOCIL project visit the project website.

The Discoveries Center mission is to perform world-leading research in regenerative and precision medicine, by anchoring research activities of the best research groups in Portugal, promoting excellence, advanced training, increasing performance, translational research outputs and commercialization strategies that can, in the long-run generate an important economic impact, besides impacting the quality of life of an ageing European population affected by neurodegenerative, cardiovascular and musculoskeletal diseases.

Learn more about The Discoveries Center here.


Clinical Research

CEDOC’s Clinical Research is conducted across the institute and its affiliated hospitals by Clinicians and Biomedical researchers. The main objective is to promote new therapeutic strategies, with considerable impact in public health.

Research Groups


Research Units


The Comprehensive Health Research Centre (CHRC) is a multidisciplinary, multi-institutional and comprehensive new research centre aimed at supporting, developing and fostering clinical, public health and health services research. The other CHRC pillars and central activities are health education and training; innovation, digital and entrepreneurship.

CHRC presentation video by CHRC Coordinator, Helena Canhão.


iNOVA4Health is a translational medicine programme organizing the efforts of biomedical researchers involved in i) biological understanding of disease, lead compounds and biopharmaceuticals pre-discovery, ii) technological scientists involved in preclinical development, and iii) clinicians involved in early clinical and first-in-man clinical trials from institutions within NOVA University of Lisbon. The programme will have a strong emphasis on developing therapies to promote healthy ageing and in targeting chronic diseases that are responsible for two thirds of deaths worldwide and a major burden on healthcare systems.



ToxOmics is a research unit that aims to carry out innovative research and advanced education and training towards a better assessment of genetics as a determinant of health - interaction between genes, environmental stress and disease causation - allowing more accurate disease prediction and prevention as well as more effective therapeutic interventions.
Interdisciplinary R&D activities use genomic and post-genomic methodologies to study the molecular, biochemical and cellular aspects of human genetic disorders and environmental stress through four interrelated approaches (i) exposure assessment and biological responses to stressors, (ii) variability in gene expression and regulation in the disease process and (iii) evaluation and development of toxicogenomic and toxicoproteomic biomarkers.